secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2023-07-18T23:59:59+00:00
Accession:  0001493152-23-024851
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow acquires VEVYE and Santen ophthalmic rights; Q2 revenue guidance >$31M
-----------------------------------------------------------------------------

- Acquired U.S./Canadian rights to VEVYE (cyclosporine 0.1%) from Novaliq; $8M upfront + low double-digit royalties.
- Acquired exclusive commercial rights to Santen ophthalmic products; $8M initial payment + milestone/royalty payments.
- Preliminary Q2 2023 revenue >$31M (vs $23.3M prior year); Adj EBITDA >$9.3M.
- Oaktree credit facility increased to $112.5M; $12.5M draw to fund Santen acquisition.
- Proposed underwritten public offering of common stock; B. Riley Securities as book-runner.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315223024851/0001493152-23-024851-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315223024851/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-024851

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer